🚀 VC round data is live in beta, check it out!
Largest Medical Devices Public Companies in the US
Benchmark revenue and EBITDA valuation multiples for public comps like
Johnson & Johnson, Thermo Fisher Scientific, Abbott, Intuitive Surgical and Danaher.
 | $234 | +50% | $564B | $592B | 6.2x | 16.5x | ||
| $527 | +23% | $196B | $225B | 5.0x | 19.8x | ||
| $97 | -26% | $168B | $173B | 3.8x | 14.2x | ||
| $469 | -9% | $167B | $161B | 15.3x | 35.4x | ||
| $195 | -2% | $138B | $153B | 6.1x | 19.5x | ||
| $343 | -8% | $131B | $143B | 5.6x | 19.4x | ||
| $86 | +2% | $111B | $130B | 3.6x | 12.8x | ||
| $64 | -38% | $95B | $105B | 5.1x | 16.2x | ||
| $589 | +36% | $47B | $48B | 10.8x | 30.6x | ||
| $81 | +7% | $47B | $43B | 6.9x | 22.7x | ||
| $122 | +13% | $34B | $36B | 5.1x | 17.4x | ||
| $75 | +6% | $34B | $40B | 1.9x | 10.7x | ||
| $22 | -15% | $33B | $32B | 5.8x | 14.9x | ||
| $328 | -6% | $32B | $33B | 8.0x | 23.8x | ||
| $1,341 | +25% | $27B | $29B | 7.2x | 22.9x | ||
| $64 | -10% | $25B | $24B | 5.0x | 16.9x | ||
| $226 | +0% | $22B | $24B | 4.0x | 14.2x | ||
| $222 | -7% | $22B | $24B | 6.7x | 21.9x | ||
| $134 | +73% | $20B | $21B | 4.9x | 17.2x | ||
| $95 | -8% | $18B | $25B | 3.0x | 9.2x | ||
| $76 | +30% | $17B | $17B | — | — | ||
| $111 | +55% | $15B | $15B | 4.8x | 15.2x | ||
| $520 | +69% | $15B | $14B | 5.5x | 25.1x | ||
| $204 | -19% | $14B | $14B | 5.0x | 20.9x | ||
| $70 | -14% | $14B | $16B | 3.8x | 12.1x | ||
| $190 | +10% | $14B | $13B | 3.1x | 11.4x | ||
| $332 | +13% | $13B | $13B | 8.7x | 45.2x | ||
| $70 | +7% | $12B | $16B | 2.0x | 7.4x | ||
| $19 | -40% | $10B | $17B | 1.5x | 8.0x | ||
| $178 | +11% | $9B | $10B | 6.3x | 20.9x | ||
| $295 | +22% | $8B | $8B | 3.0x | 17.0x | ||
| $125 | +32% | $7B | $7B | 13.2x | (405.1x) | ||
| $41 | +2% | $6B | $8B | 2.3x | 13.8x | ||
| $21 | -- | $6B | $6B | 6.4x | 39.3x | ||
| $132 | -4% | $6B | $8B | 3.9x | 13.8x | ||
| $20 | +22% | $5B | $6B | 5.8x | 23.3x | ||
| $129 | +8% | $5B | $5B | 4.5x | 19.7x | ||
| $28 | +73% | $5B | $5B | 1.8x | 12.9x | ||
| $71 | -25% | $4B | $5B | 3.0x | 11.9x | ||
| $14 | -- | $4B | $4B | — | — | ||
| $125 | +17% | $4B | $4B | 5.3x | 52.8x | ||
| $116 | +26% | $4B | $4B | 6.2x | 25.2x | ||
| $67 | +81% | $4B | $3B | 2.4x | 10.8x | ||
| $80 | -- | $4B | $3B | 9.5x | 78.6x | ||
| $130 | -5% | $3B | $4B | 1.9x | 10.5x | ||
| $90 | -29% | $3B | $4B | 2.4x | 10.9x | ||
| $62 | -2% | $3B | $4B | 2.8x | 8.9x | ||
| $114 | +26% | $3B | $2B | 9.4x | 30.9x | ||
| $38 | +137% | $2B | $2B | 8.5x | 72.1x | ||
| $38 | +59% | $2B | $2B | 4.4x | 21.4x | ||
| $13 | +50% | $2B | $4B | 1.1x | 5.5x | ||
| $11 | +1% | $2B | $2B | 2.6x | 20.1x | ||
| $58 | -64% | $2B | $1B | 1.5x | 6.7x | ||
| $31 | +4% | $2B | $1B | 2.8x | (28.7x) | ||
| $23 | +37% | $2B | $2B | 1182.8x | (28.3x) | ||
| $202 | -3% | $2B | $2B | 2.8x | 13.7x | ||
| $26 | -24% | $2B | $3B | 1.3x | 7.0x | ||
| $30 | -1% | $2B | $1B | 2.5x | 20.9x | ||
| $13 | -29% | $1B | $1B | 1.9x | (47.1x) | ||
| $25 | -53% | $1B | $1B | 3.6x | (28.2x) | ||
| $21 | +22% | $1B | $2B | 1.5x | (105.1x) | ||
| $5 | +133% | $1B | $1B | 12.2x | (48.4x) | ||
| $1 | -86% | $1B | $1B | — | — | ||
| $25 | +37% | $1B | $1B | 4.2x | 174.3x | ||
| $93 | +78% | $1B | $1B | 13.2x | 40.8x | ||
| $39 | -20% | $1B | $2B | 1.4x | 7.2x | ||
| $25 | +96% | $1B | $1B | 1.7x | 13.5x | ||
| $15 | +4% | $928M | $381M | 1.0x | 4.1x | ||
| $11 | -32% | $869M | $3B | 1.6x | 8.3x | ||
| $13 | -54% | $865M | $4B | 1.3x | 5.9x | ||
| $21 | +33% | $797M | $660M | 6.9x | (12.7x) | ||
| $11 | +44% | $708M | $951M | 1.6x | 8.1x | ||
| $14 | +3% | $622M | $511M | 2.4x | 54.7x | ||
| $5 | +24% | $593M | $355M | 1.7x | 383.6x | ||
| $6 | +23% | $590M | $580M | 142.2x | (6.0x) | ||
| $26 | +82% | $585M | $502M | 1.5x | 10.9x | ||
| $13 | +18% | $579M | $367M | 3.3x | (6.3x) | ||
| $103 | -11% | $569M | $721M | 2.9x | 11.8x | ||
| $16 | +38% | $544M | $554M | 5.6x | (76.0x) | ||
| $13 | -9% | $511M | $607M | 0.7x | 7.0x | ||
| $3 | -50% | $507M | $359M | 0.9x | 4.1x | ||
| $10 | -- | $495M | $423M | — | — | ||
| $5 | -31% | $480M | $540M | 0.6x | 14.0x | ||
| $4 | +71% | $479M | $337M | 408.8x | (2.7x) | ||
| $1 | +29% | $476M | $461M | 366.6x | (21.7x) | ||
| $11 | +17% | $449M | $409M | 1.3x | 34.5x | ||
| $17 | -20% | $423M | $462M | 1.9x | 26.0x | ||
| $2 | +58% | $400M | $414M | 1.7x | 39.5x | ||
| $10 | +38% | $376M | $378M | 1.3x | 6.0x | ||
| $11 | -10% | $375M | $285M | 3.1x | 17.9x | ||
| $1 | -16% | $364M | $207M | 2.5x | (4.0x) | ||
| $12 | -18% | $354M | $366M | 8.8x | (23.5x) | ||
| $8 | -48% | $314M | $97M | 0.7x | (2.1x) | ||
| $20 | -- | $311M | $417M | — | — | ||
| $15 | -- | $310M | $200M | 3.8x | (6.0x) | ||
| $6 | -- | $300M | $290M | 20.4x | (11.6x) | ||
| $11 | -- | $293M | $200M | 3.5x | (6.5x) | ||
| $5 | -9% | $286M | $300M | 6.0x | (23.5x) | ||
| $7 | -55% | $283M | $230M | 5.4x | — | ||
| $5 | +54% | $268M | $177M | 7.4x | (2.7x) |
Financial data powered by FactSet and Morningstar. Valuation multiples as of last 12 months. For more data, start your free trial here.
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.